Tags

Type your tag names separated by a space and hit enter

Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium.
Eur Respir J. 2002 Feb; 19(2):209-16.ER

Abstract

Tiotropium, a novel once-daily inhaled anticholinergic, has been shown to improve lung function over a 24-h period. In order to extend these findings, health-outcomes were evaluated over 1 yr in chronic obstructive pulmonary disease (COPD) patients. Spirometric results, peak expiratory flow rate (PEFR), salbutamol use and effects on dyspnoea, health-related quality of life and COPD exacerbations were assessed in two identical 1-yr randomized double-blind double-dummy studies of tiotropium 18 microg once daily (n=356) compared with ipratropium 40 microg q.i.d. (n=179). Screening forced expiratory volume in one second (FEV1) were 1.25+/-0.43 L (41.9+/-12.7% of the predicted value) (tiotropium) and 1.18+/-0.37 L (39.4+/-10.7% pred) (ipratropium). Trough FEV1 at 1 yr improved by 0.12+/-0.01 L with tiotropium and declined by 0.03+/-0.02 L with ipratropium (p<0.001). Significant improvement in PEFR, salbutamol use, Transition Dyspnea Index focal score, and the St George's Respiratory Questionnaire total and impact scores were seen with tiotropium (p<0.01). Tiotropium reduced the number of exacerbations (by 24%, p<0.01), and increased time to first exacerbation (p<0.01) and time to first hospitalization for a COPD exacerbation (p<0.05) compared with ipratropium. Apart from an increased incidence of dry mouth in the tiotropium group, adverse events were similar between treatments. Tiotropium was effective in improving dyspnoea, exacerbations, health-related quality of life and lung function in patients with chronic obstructive pulmonary disease, and exceeds the benefits seen with ipratropium. The data support the use of tiotropium once-daily as first-line maintenance treatment in patients with chronic obstructive pulmonary disease.

Authors+Show Affiliations

Respiratory Division, AZ VUB (Academic Hospital University of Brussels), Belgium.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

11871363

Citation

Vincken, W, et al. "Improved Health Outcomes in Patients With COPD During 1 Yr's Treatment With Tiotropium." The European Respiratory Journal, vol. 19, no. 2, 2002, pp. 209-16.
Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J. 2002;19(2):209-16.
Vincken, W., van Noord, J. A., Greefhorst, A. P., Bantje, T. A., Kesten, S., Korducki, L., & Cornelissen, P. J. (2002). Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. The European Respiratory Journal, 19(2), 209-16.
Vincken W, et al. Improved Health Outcomes in Patients With COPD During 1 Yr's Treatment With Tiotropium. Eur Respir J. 2002;19(2):209-16. PubMed PMID: 11871363.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. AU - Vincken,W, AU - van Noord,J A, AU - Greefhorst,A P M, AU - Bantje,Th A, AU - Kesten,S, AU - Korducki,L, AU - Cornelissen,P J G, AU - ,, PY - 2002/3/2/pubmed PY - 2002/8/23/medline PY - 2002/3/2/entrez SP - 209 EP - 16 JF - The European respiratory journal JO - Eur. Respir. J. VL - 19 IS - 2 N2 - Tiotropium, a novel once-daily inhaled anticholinergic, has been shown to improve lung function over a 24-h period. In order to extend these findings, health-outcomes were evaluated over 1 yr in chronic obstructive pulmonary disease (COPD) patients. Spirometric results, peak expiratory flow rate (PEFR), salbutamol use and effects on dyspnoea, health-related quality of life and COPD exacerbations were assessed in two identical 1-yr randomized double-blind double-dummy studies of tiotropium 18 microg once daily (n=356) compared with ipratropium 40 microg q.i.d. (n=179). Screening forced expiratory volume in one second (FEV1) were 1.25+/-0.43 L (41.9+/-12.7% of the predicted value) (tiotropium) and 1.18+/-0.37 L (39.4+/-10.7% pred) (ipratropium). Trough FEV1 at 1 yr improved by 0.12+/-0.01 L with tiotropium and declined by 0.03+/-0.02 L with ipratropium (p<0.001). Significant improvement in PEFR, salbutamol use, Transition Dyspnea Index focal score, and the St George's Respiratory Questionnaire total and impact scores were seen with tiotropium (p<0.01). Tiotropium reduced the number of exacerbations (by 24%, p<0.01), and increased time to first exacerbation (p<0.01) and time to first hospitalization for a COPD exacerbation (p<0.05) compared with ipratropium. Apart from an increased incidence of dry mouth in the tiotropium group, adverse events were similar between treatments. Tiotropium was effective in improving dyspnoea, exacerbations, health-related quality of life and lung function in patients with chronic obstructive pulmonary disease, and exceeds the benefits seen with ipratropium. The data support the use of tiotropium once-daily as first-line maintenance treatment in patients with chronic obstructive pulmonary disease. SN - 0903-1936 UR - https://www.unboundmedicine.com/medline/citation/11871363/Improved_health_outcomes_in_patients_with_COPD_during_1_yr's_treatment_with_tiotropium_ L2 - http://erj.ersjournals.com/cgi/pmidlookup?view=long&amp;pmid=11871363 DB - PRIME DP - Unbound Medicine ER -